Altered T cell development in human thymorea is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-γ)

Clinical and Experimental Immunology

Volumn 121, Issue 1, 2000, Pages 59-68

  Kadota, Y ^a   Okumura, Meinoshin ^a   Miyoshi, S ^a   Kitagawa Sakakida, S ^a   Inoue, M ^a   Shiono, H ^a   Maeda, Y ^b   Kinoshita, T ^b   Shirakura, R ^a   Matsuda, H ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Invariant chain; MHC class II transactivator; T cell development; Thymic epithelial tumour myasthenia gravis

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ARTICLE; CELL MATURATION; GEL MOBILITY SHIFT ASSAY; GENE TRANSLOCATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MYASTHENIA GRAVIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYMOMA; TRANSACTIVATION;

ADOLESCENT; ADULT; AGED; EPITHELIAL CELLS; GENE EXPRESSION; HLA-DR ANTIGENS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; MIDDLE AGED; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; THYMOMA; THYMUS GLAND; THYMUS NEOPLASMS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0033934538     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01256.x     Document Type: Article

References (54)

1. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 1978; 9:495-515.
2. Willcox N. Myasthenia gravis. Curr Opin Immunol 1993; 5:910-7.
3. Levinson AI, Wheatley LM. The thymus and the pathogenesis of myasthenia gravis. Clin Immunol Immunopathol 1996; 78:1-5.
4. Rosai J, Levine GD. Atlas of tumor pathology. Tumors of the thymus. Washington: Armed Forces Institute of Pathology, 1976.
5. Pedraza MA. Thymoma immunological and ultrastructural characterization. Cancer 1977; 39:1455-61.
6. Lauriola L, Maggiano N, Marino M, Carbone A, Piantelli M, Musiani P. Human thymoma: immunologic characteristics of the lymphocytic component. Cancer 1981; 48:1992-5.
7. Palestro G, Geuna M, Novero D, Godio L, Ciccone G, Azzoni L. Immunophenotype of thymoma-associated lymphoid cell component of T-cell type. A new analytic procedure in keeping with structural heterogeneities. Virchows Arch B Cell Pathol 1990; 59:297-304.
8. Fujii Y, Hayakawa M, Inada K, Nakahara K. Lymphocytes in thymoma: association with myasthenia gravis is correlated with increased number of single-positive cells. Eur J Immunol 1990; 20:2355-8.
9. Inoue M, Fujii Y, Okumura M, Takeuchi Y, Shiono H, Miyoshi S, Matsuda H. Neoplastic thymic epithelial cells of human thymoma support T cell development from CD4-CD8- cells to CD4+CD8+ cells in vivo. Clin Exp Immunol 1998; 112:419-26.
10. Inoue M, Okumura M, Fujii Y, Miyoshi S, Shiono H, Fukuhara K, Kadota Y, Matsuda H. Immaturity of lymphocytes in the metastatic lesions of thymoma. Clin Immunol Immunopathol 1998; 88:249-55.
11. Takeuchi Y, Fujii Y, Okumura M, Inada K, Nakahara K, Matsuda H. Accumulation of immature CD3-CD4+CD8- single-positive cells that lack CD69 in epithelial cell tumors of the human thymus. Cell Immunol 1995; 161:181-7.
12. Inoue M, Okumura M, Miyoshi S, Shiono H, Fukuhara K, Kadota Y, Shirakura R, Matsuda H. Impaired expression of MHC class II molecules in response to interferon-gamma (IFN-gamma) on human thymoma neoplastic epithelial cells. Clin Exp Immunol 1999; 117:1-7.
13. Nenninger R, Schultz A, Hoffacker V et al. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab Invest 1998; 78:743-53.
14. Willcox N, Schluep M, Ritter MA, Schuurman HJ, Newsom-Davis J, Christensson B. Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol 1987; 127:447-60.
15. Sprent J. T lymphocytes and the thymus. Fundamental immunology, 3rd edn. New York: Raven Press, 1993:75-109.
16. Hugo P, Kappler JW, Marrack PC. Positive selection of TcR alpha beta thymocytes: is cortical thymic epithelium an obligatory participant in the presentation of major histocompatibility complex protein? Immunol Rev 1993; 135:133-55.
17. Fink PJ, Bevan MJ. Positive selection of thymocytes. Adv Immunol 1995; 59:99-133.
18. Bach EA, Aguet M, Schreiber RD. The IFNgamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997; 15:563-91.
19. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15:749-95.
20. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 1996; 14:301-31.
21. Boss JM. Regulation of transcription of MHC class II genes. Curr Opin Immunol 1997; 9:107-13.
22. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of a MHC Class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75:135-46.
23. Chang CH, Guerder S, Hong SC, van Ewijk W, Flavell RA. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 1996; 4:167-78.
24. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 1991; 67:1025-32.
25. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48:2485-92.
26. Rosasi J, in collabolation with Sobin LH and pathologists from 8 countries. Histological typing of tumors of the thymus. In: World Health Organization international histological classification of tumors, 2nd edn. Berlin: Springer, 1999:9-13.
27. Young IT. Proof without prejudice: use of the Kolmogorov-Smirnov test for analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977; 25:935-41.
28. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11:1475-89.
29. Orlando C, Pinzani P, Pazzagli M. Developments in quantitative PCR. Clin Chem Lab Med 1998; 36:255-69.
30. Ritter MA, Boyd RL. Development in the thymus: it takes two to tango. Immunol Today 1993; 14:462-9.
31. Spitz H, Blom B, Jaleco A-C, Weijer K, Verschuren MCM, van Dongen JJM, Heemskerk MHM, Res PCM. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol Rev 1998; 165:75-86.
32. Stratowa C, Audette M. Transcriptional regulation of human intra-cellular adhesion molecule-1 gene: a short overview. Immunobiol 1995; 193:293-304.
33. Le PT, Singer KH. Human thymic epithelial cells: adhesion molecules and cytokine production. Int J Clin Lab Res 1993; 23:56-60.
34. Otten LA, Steimle V, Bontron S, Mach B. Quantitative control of MHC class II expression by the transactivator CIITA. Eur J Immunol 1998; 28:473-8.
35. Chang CH, Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 1995; 181:765-7.
36. Muhlethaler-Mottet A, Di Berardino W, Otten LA, Mach B. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 1998; 8:157-66.
37. Schuurman HJ, van de Wijngaert FP, Huber J et al. The thymus in bare lymphocyte syndrome: significance of expression of major histocompatibility complex antigen on thymic epithelial cells in intrathymic T-cell maturation. Hum Immunol 1985; 13:69.
38. Inoue M, Fujii Y, Okumura M et al. Mature CD4 single positive thymocytes in human thymoma: T cell may differentiate in the thymic epithelial cell tumor. Pathobiology 1997; 65:216-22.
39. Muller-Hermelink HK, Wilisch A, Schultz A, Marx A. Characterization of the human thymic microenvironment: lymphoepithelial interaction in normal thymus and thymoma. Arch Histol Cytol 1997; 60:9-28.
40. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997; 16:2851-60.
41. Dong Y, Wolfgang MR, Benveniste EN. IFN-γ regulation of type IV class II transactivator promoter in astrocytes. J Immunol 1999; 162:4731-9.
42. Steimle V, Durand B, Barras EZ, Hadam MR, Mach B, Reith W. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995; 9:1021-32.
43. Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity 1999; 10:143-51.
44. Fontes JD, Kanazawa S, Jean D, Peterlin BM. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol Cell Biol 1999; 19:941-7.
45. Kretsovali A, Agalioti T, Spilianakis C, Tzortzakaki E, Merika M, Papamatheakis J. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator. Mol Cell Biol 1998; 18:6777-83.
46. Gobin SJ, Peijnenburg A, van Eggermond M, van Zutphen M, van den Berg R, van den Elsen PJ. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes. Immunity 1998; 9:531-41.
47. O'Keefe GM, Nguyen VT, Benveniste EN. Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10. Eur J Immunol 1999; 29:1275-85.
48. Fukai Y, Ishimoto T, Utsuyama M et al. Positive and negative CD4+ thymocyte selection by a single MHC class II/peptide ligand affected by its expression level in the thymus. Immunity 1997; 6:401-10.
49. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76:17-27.
50. Ashton-Rickardt PG, Tonegawa S. A differential-avidity model for T-cell selection. Immunol Today 1994; 362:366.
51. Jameson SC, Hogquist KA, Bevan MJ. Positive selection of thymocytes. Annu Rev Immunol 1995; 13:93-126.
52. Salmon AM, Bruand C, Cardona A, Changeux JP, Berrih-Aknin S. An acetylcholine receptor alpha subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self antigen and for autoreactivity in myasthenia gravis. J Clin Invest 1998; 101:2340-50.
53. Wilisch A, Gutsche S, Hoffacker V et al. Association of acetylcholine receptor alpha subunit gene expression in mixed thymoma with myasthenia gravis. Neurology 1999; 52:1460-6.
54. Nagvekar N, Moody AM, Moss P et al. A pathogenic role for the thymoma in myasthenia gravis. J Clin Invest 1997; 101:2268-77.